Biogen Inc. (NASDAQ:BIIB) Stock Has Average Price Target of $231.07 According to Brokerages

Posted by Francis Steltz on Oct 13th, 2026

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the thirty-two analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $236.04.

BIIB has been the topic of several recent research reports. Guggenheim boosted their price target on Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Citigroup upped their price target on Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $245.00 price objective (up from $225.00) on shares of Biogen in a research report on Thursday, September 3rd. UBS Group lifted their price objective on shares of Biogen from $240.00 to $270.00 and gave the company a “buy” rating in a research note on Friday. Finally, Bank of America reduced their target price on shares of Biogen from $217.00 to $215.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 21st.

Get Our Latest Report on BIIB

Biogen News Summary

Here are the key news stories impacting Biogen this week:

Positive Sentiment: J.P. Morgan said Biogen has an increasingly compelling catalyst path, highlighting potential 2027 data readouts for felzartamab in antibody-mediated rejection and litifilimab in cutaneous lupus erythematosus (CLE). The new target implies substantial upside from recent trading levels. JPMorgan Upgrades Biogen to Overweight From Neutral
Positive Sentiment: Biogen’s 52-week Phase 2 AMETHYST data for litifilimab showed sustained improvements in skin disease activity among difficult-to-treat CLE patients, with a generally well-tolerated safety profile. The program also has FDA Breakthrough Therapy Designation, supporting its potential as a first-in-class, once-monthly treatment. What Biogen’s 52-Week Litifilimab CLE Data Means
Positive Sentiment: Recent pipeline updates have strengthened the view that Biogen’s investment case is becoming less dependent on its Alzheimer’s franchise. The stock has also delivered strong recent performance, while one analysis characterized the shares as modestly undervalued despite that run. Biogen Could Be Undervalued After 52-Week Lupus Data
Neutral Sentiment: Biogen is scheduled to report third-quarter 2026 results on October 28. The release could provide a near-term confirmation of operating trends and updated expectations ahead of the larger 2027 clinical catalysts.
Neutral Sentiment: Institutional positioning was mixed in the latest reported quarter: several large investors, including FMR and JPMorgan, increased holdings, while VanEck, Point72 and T. Rowe Price reduced positions. This suggests improving interest but not uniform conviction.
Negative Sentiment: Reported insider activity was limited but consisted of two sales and no purchases over the past six months. While not a major catalyst compared with the analyst upgrade, it provides a modest counterpoint to the bullish sentiment.

Biogen Trading Up 1.6%

NASDAQ:BIIB opened at $229.41 on Friday. The business’s 50-day moving average is $217.96 and its two-hundred day moving average is $202.72. The firm has a market capitalization of $33.90 billion, a PE ratio of 40.60, a price-to-earnings-growth ratio of 2.49 and a beta of 0.09. Biogen has a 12 month low of $138.00 and a 12 month high of $238.24. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB – Get Free Report) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The company had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same quarter in the prior year, the business earned $5.47 earnings per share. The company’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Research analysts predict that Biogen will post 12.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Biogen

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Biogen during the 2nd quarter valued at approximately $3,453,878,000. Primecap Management Co. CA bought a new position in Biogen during the 2nd quarter worth $3,274,304,000. Wellington Management Group LLP grew its stake in Biogen by 5.3% during the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after buying an additional 155,828 shares during the last quarter. Amundi increased its position in Biogen by 91.8% in the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock worth $327,727,000 after buying an additional 726,004 shares during the period. Finally, Legal & General Group Plc acquired a new stake in Biogen in the second quarter worth $322,640,000. 87.93% of the stock is owned by institutional investors and hedge funds.

About Biogen

(Get Free Report)

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.